Cannabidiol for people with schizophrenia

Diana Buitrago-Garcia; Guillermo Sánchez Vanegas; Paula Alejandra Sánchez Correa; Stela del pilar Baracaldo; Santiago Felipe Gallego Gallego; Lone Baandrup

doi:10.1002/14651858.CD014602

Cannabidiol for people with schizophrenia

Diana Buitrago-Garcia, Guillermo Sánchez Vanegas, Paula Alejandra Sánchez Correa, Stela del pilar Baracaldo, Santiago Felipe Gallego Gallego, Lone Baandrup

Scientific Direction

Research output: Contribution to journal › Article › peer-review

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effectiveness and safety of CBD in the treatment of people with schizophrenia.

Original language	English
Article number	CD014602
Pages (from-to)	1-15
Number of pages	15
Journal	Cochrane Database of Systematic Reviews
Volume	2022
Issue number	11
DOIs	https://doi.org/10.1002/14651858.CD014602 https://doi.org/10.1002/14651858.CD014602
State	Published - 16 Nov 2022

Keywords

Cannabidiol
Schizophrenia
Protocol

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Cite this

@article{5d00350c17e348b7b07e1f938193f1f3,

title = "Cannabidiol for people with schizophrenia",

abstract = "Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effectiveness and safety of CBD in the treatment of people with schizophrenia.",

keywords = "Cannabidiol, Schizophrenia, Protocol",

author = "Diana Buitrago-Garcia and {S{\'a}nchez Vanegas}, Guillermo and {S{\'a}nchez Correa}, {Paula Alejandra} and Baracaldo, {Stela del pilar} and {Gallego Gallego}, {Santiago Felipe} and Lone Baandrup",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.",

year = "2022",

month = nov,

day = "16",

doi = "10.1002/14651858.CD014602",

language = "Ingl{\'e}s",

volume = "2022",

pages = "1--15",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "John Wiley and Sons Ltd",

number = "11",

}

TY - JOUR

T1 - Cannabidiol for people with schizophrenia

AU - Buitrago-Garcia, Diana

AU - Sánchez Vanegas, Guillermo

AU - Sánchez Correa, Paula Alejandra

AU - Baracaldo, Stela del pilar

AU - Gallego Gallego, Santiago Felipe

AU - Baandrup, Lone

PY - 2022/11/16

Y1 - 2022/11/16

N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effectiveness and safety of CBD in the treatment of people with schizophrenia.

AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effectiveness and safety of CBD in the treatment of people with schizophrenia.

KW - Cannabidiol

KW - Schizophrenia

KW - Protocol

UR - http://www.scopus.com/inward/record.url?scp=85142045544&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD014602

DO - 10.1002/14651858.CD014602

M3 - Artículo

AN - SCOPUS:85142045544

SN - 1465-1858

VL - 2022

SP - 1

EP - 15

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 11

M1 - CD014602

ER -

Cannabidiol for people with schizophrenia

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this